PacificHealth Laboratories Updates Launch of ACCELERADE(R) Ready-to-Drink.

MATAWAN, N.J. -- PacificHealth Laboratories, Inc. (OTCBB: PHLI), a nutrition technology company, said that at an Investors Conference held in London yesterday, Todd Stitzer, CEO of Cadbury Schweppes, officially announced the national multi-channel launch of ACCELERADE RTD. Product will be shipped in the second quarter. ACCELERADE is part of a major innovation drive by Cadbury Schweppes. Because of its proven benefits, Stitzer described ACCELERADE as the "holy grail" for serious exercisers. To hear the Feb 20 presentation, go to www.cadburyschweppes.com/EN/InvestorCentre/Presentations/.

ACCELERADE was part of an asset purchase agreement between PacificHealth Laboratories and Motts, LLP, a division of Cadbury Schweppes Americas Beverage ("CSAB"). Under the terms of the agreement PHLI received an upfront payment of $4 million, a royalty payment for a finite period of time and a royalty-free license to continue selling ACCELERADE and ENDUROX R4[R] in powder and gel forms.

Dr. Robert Portman, Chairman and CEO of PHLI said, "We have been working closely with CSAB for the past year in coordinating our efforts. We have completely revamped all of the ACCELERADE powder and ACCEL GEL([R]) packaging so that it is consistent with the new RTD label. Additionally, we have instituted an aggressive program involving the placement of permanent point of purchase displays in leading sports specialty stores. I anticipate that the marketing and advertising efforts by Cadbury in supporting the ACCELERADE brand will have a significant benefit to powder and gel sales. We are implementing a number of programs to fully take advantage of this opportunity."

ACCELERADE, developed by PacificHealth Laboratories, is the first sports drink that contains a patented 4:1 ratio of carbohydrate to protein. Fifteen studies have now been conducted documenting the benefits of a 4:1 ratio in terms of improved endurance, enhanced rehydration, faster muscle recovery and less post-exercise muscle damage. For more information visit www.accelerade.com.

About PacificHealth Laboratories, Inc.:

PacificHealth Laboratories, Inc. (PHLI.OB), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principle areas of focus include weight loss, management of Type 2 diabetes and sports performance. To learn more, visit www.pacifichealthlabs.com.

This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.